SCHEMBL20189376

SCHEMBL20189376

N#Cc1ccc(CN2CC(=O)NC2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.46
EPHX2 P34913 1/20 0.44
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
CYP19A1 P11511 1/20 0.44
GAA P10253 1/20 0.42
HTR2C P28335 1/20 0.42
MAPK1 P28482 2/20 0.42
TSHR P16473 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP2D6 P10635 2/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 1/20 0.41
PRMT5 O14744 3/20 0.40
WDR77 Q9BQA1 3/20 0.40
CYP3A4 P08684 2/20 0.40
COMT P21964 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9164640 0.80 EPHX2 (0.49) EPHX2DDB1CRBNGAAMEN1
SCHEMBL20189142 0.78 EPHX2 (0.47) EPHX2DDB1CRBNGAAMAPK1
SCHEMBL28757730 0.78 EPHX2 (0.47) EPHX2DDB1CRBNGAATSHR
SCHEMBL8009140 0.78 EPHX2 (0.47) EPHX2DDB1CRBNCYP19A1GAA
SCHEMBL840894 0.78 EPHX2 (0.47) EPHX2DDB1CRBNGAAMAPK1
SCHEMBL9850086 0.78 DDB1 (0.69) EPHX2DDB1CRBNGAATSHR
SCHEMBL1011633 0.78 DDB1 (0.69) EPHX2DDB1CRBNGAATSHR
SCHEMBL8136911 0.77 POLB (0.65) USP2CYP19A1HTR2CMAPK1TSHR
SCHEMBL7436022 0.76 PRMT5 (0.55) USP2CYP19A1MAPK1TSHRSMN1; SMN2
SCHEMBL9850110 0.76 DDB1 (0.67) EPHX2DDB1CRBNGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168059-B2 Amino sulfonyl compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-09 US disclosed
US-11168059-B2 Amino sulfonyl compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-09 US disclosed
US-20190330158-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 US disclosed
US-20190330158-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 US disclosed
WO-2018098209-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-05-31 WO disclosed
WO-2018098209-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168059-B2 Amino sulfonyl compounds DPYD, DNPEP, DUT USP2 919/4885EPHX2 2947/4885DDB1 33/4885
US-20190330158-A1 AMINO SULFONYL COMPOUNDS DPYD, DNPEP, DUT USP2 919/4885EPHX2 2947/4885DDB1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.